Roche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022
New positive data fromEvrysdi, a treatment for spinal muscular atrophy (SMA), a progressive neuromuscular disease that can be fatalData from the gene therapyprogramme forDuchenne muscular dystrophy (DMD), a progressive disease that leads to premature death, reinforce confidence in the most advanced Phase 3 study currently underwayStudy designs of two new trials ingeneralised myasthenia gravis (gMG), a rare chronic autoimmune disease, andfacioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorderBasel, 05 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its industry-leading neuromuscular portfolio will be presented at the World Muscle Society (WMS) congress, 11th-15th October 2022. These data demonstrate Roche ’s commitment to advancing clinical understanding and supporting the development of treatments for people living with neuromuscular disorders.“The continued expansion of our neuromuscular portfolio demonstrates our commitment to developing innovative medicines for a range of neurological disorders,” said Levi Garraway, M.D., Ph. D., Roche’s Chief Medical Officer and Head of Global Product Development. “Through our ongoing research and development and our strong partnerships with patient communities, we continue to address the needs of people with rare neuromuscular conditions.”Spinal muscular atrophy (SMA)SMA is a severe, progressive neuromuscular disease that can be fatal. It is the leading genetic cause of in...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Alzheimer's | Autoimmune Disease | Babies | Biotechnology | Boys | Brain | Child Development | Children | Clinical Trials | Encephalitis | European Medicines Agency (EMA) | Facioscapulohumeral Muscular Dystrophy (FSHD) | Food and Drug Administration (FDA) | Gene Therapy | Genetics | Japan Health | Men | Motor Neurone Disease | Multiple Sclerosis | Muscular Dystrophy | Myasthenia Gravis | Neurology | Neuroscience | Partnerships | Perinatology & Neonatology | Pharmaceuticals | Politics | Reflex Sympathetic Dystrophy | Respiratory Medicine | Russia Health | Science | Spinal Muscular Atrophy | Study | Switzerland Health | UK Health | USA Health | Websites